Tag

Zai Lab Limited

1 article

Zai Lab Shares Rise 2.6% on Trial

Zai Lab shares rose 2.6% after releasing positive Phase 1 data for its DLL3‑targeting ADC “zoci” in small‑cell lung cancer. The drug showed a 62.5% confirmed intracranial response at 1.6 mg/kg among 1